- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06542874
Eine Forschungsstudie, die vergleicht, wie gut verschiedene Dosen des Arzneimittels NNC0487-0111 den Blutzucker bei Menschen mit Typ-2-Diabetes senken
Sicherheit und Wirksamkeit der einmal wöchentlichen subkutanen und einmal täglichen oralen Verabreichung von NNC0487-0111 bei Teilnehmern mit Typ-2-Diabetes – eine Dosisfindungsstudie
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Kyustendil, Bulgarien, 2500
- Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
-
Kyustendil, Bulgarien, 2500
- IPSOMC Dr. Miglena Rizova Ltd.
-
Plovdiv, Bulgarien, 4002
- DCC Sveti Georgi EOOD
-
Plovdiv, Bulgarien, 4001
- UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
-
Plovdiv, Bulgarien, 4002
- Diagnostic-Consultative Centre "Sveti Georgi" Eood
-
Plovdiv, Bulgarien, 4001
- UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
-
Sofia, Bulgarien, 1431
- USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
-
Sofia, Bulgarien, 1431
- UMHAT "Aleksandrovska"
-
Sofia, Bulgarien, 1000
- Medical centre Regina Life Clinic EOOD
-
Sofia, Bulgarien, 1431
- USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
-
Sofia, Bulgarien, 1431
- UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
-
Varna, Bulgarien, 9020
- AIPSMC Dr. Artin Magardichyan EOOD
-
-
-
-
-
Elsterwerda, Deutschland, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Elsterwerda, Deutschland, 04910
- Zentrum fuer klinische Studien Suedbrandenburg GmbH
-
Essen, Deutschland, 45136
- InnoDiab Forschung GmbH
-
Hamburg, Deutschland, 22607
- Wendisch/Dahl Hamburg
-
Hamburg, Deutschland, 22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster, Deutschland, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, Deutschland, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Athens, Griechenland, 115 25
- Iatriko Psychicou Private Clinic
-
Athens, Griechenland, 12462
- U.G.H of Athens "Attikon"
-
Goudi/Athens, Griechenland, 11527
- "Laiko" General Hospital of Athens
-
Thessaloniki, Griechenland, GR-54643
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Griechenland, GR-57001
- "Thermi" Private Hosital
-
Thessaloniki, Griechenland, 564 29
- 424 Military General Training Hospital
-
Thessaloniki, Griechenland, 57001
- "Thermi" Private Hosital
-
Thessaloniki, Griechenland, 54645
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Griechenland, 564 29
- 424 Military General Training Hospital - 2nd Department of Internal Medicine
-
-
-
-
-
Aichi, Japan, 468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Chiba, Japan, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Chiba, Japan, 261-0004
- Tokuyama clinic
-
Chiba-shi, Chiba, Japan, 260-0804
- Akaicho Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japan, 880-0034
- Heiwadai Hospital_Internal Medicine
-
Miyazaki, Miyazaki, Japan, 880-0034
- Heiwadai Hospital
-
-
-
-
-
Karlovac, Kroatien, 47000
- Opca bolnica Karlovac
-
Krapinske Toplice, Kroatien, 49217
- Specijalna bolnica Krapinske Toplice - Endokrinologija
-
Krapinske Toplice, Kroatien, 49217
- Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
-
Osijek, Kroatien, 31 000
- Klinicki bolnicki centar Osijek_Endocrinology
-
Osijek, Kroatien, 31 000
- Klinicki bolnicki centar Osijek
-
Varaždin, Kroatien, 42 000
- Opca bolnica Varazdin_Endocrinology
-
Varaždin, Kroatien, 42 000
- Opca bolnica Varazdin
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Kroatien, 10000
- Poliklinika Solmed
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, Kroatien, 51 000
- KBC Rijeka, Endokrinologija
-
Rijeka, Primorje-Gorski Kotar County, Kroatien, 51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
-
Bialystok, Polen, 15-375
- Specderm Poznańska Spółka Jawna
-
Lublin, Polen, 20-718
- EKAMED sp. z o.o.
-
Ruda Śląska, Polen, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
Warsaw, Polen, 02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
-
Gornoslaskie
-
Ruda Śląska, Gornoslaskie, Polen, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31-261
- Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
-
Oświęcim, Lesser Poland Voivodeship, Polen, 32-600
- Formed 2 Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Legnica, Lower Silesian Voivodeship, Polen, 59-220
- Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
-
Legnica, Lower Silesian Voivodeship, Polen, 59-220
- Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-718
- EKAMED sp. z o.o.
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polen, 08-110
- ETG Siedlce
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-879
- NZOZ Vita-Diabetica Malgorzata Buraczyk
-
Bialystok, Podlaskie Voivodeship, Polen, 15-375
- Specderm Poznanska Sp. j.
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polen, 90-302
- Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
-
-
-
-
-
Brasov, Rumänien, 500101
- Mariodiab Clinic SRL
-
Timișoara, Rumänien, 300723
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
-
Timișoara, Rumänien, 300288
- Cabinet Medical Dr Geru SRL
-
-
Bihor County
-
Oradea, Bihor County, Rumänien, 410025
- SC Grand Med SRL
-
Oradea, Bihor County, Rumänien, 410159
- Grandmed SRL
-
-
Bucharest
-
Bucharest, Bucharest, Rumänien, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Bucurestii
-
Bucharest, Bucurestii, Rumänien, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumänien, 400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Târgu Mureş, Mureș County, Rumänien, 540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti, Prahova, Rumänien, 100018
- Novus Medical Clinica SRL
-
-
-
-
-
Poprad, Slowakei, 05801
- DENTAVIA s.r.o.
-
Prešov, Slowakei, 080 01
- DIABETOL, s.r.o.
-
Rimavská Sobota, Slowakei, 979 01
- OLIVER - MED s.r.o.
-
Žilina, Slowakei, 010 01
- MEDIVASA, s.r.o., Diabetologicka ambulancia
-
-
Slovak Republic
-
Šahy, Slovak Republic, Slowakei, 93601
- Peter Farkas MD, s.r.o.
-
-
-
-
-
A Coruña, Spanien, 15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona, Spanien, 08036
- Hospital Clinic i Provincial
-
Castilleja de la Cuesta, Spanien, 41950
- Hospital Vithas Sevilla
-
Madrid, Spanien, 28007
- Hospital Gregorio Marañón
-
Pontevedra, Spanien
- Complejo Hospitalario de Pontevedra - Hospital de Montecelo
-
Santander, Spanien, 39008
- Hospital Universitario Marqués de Valdecilla
-
Seville, Spanien, 41003
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología
-
Seville, Spanien, 41010
- Hospital Infanta Luisa
-
Seville, Spanien, 41950
- Hospital Nisa Sevilla Aljarafe
-
Seville, Spanien, 41010
- H. Infanta Luisa_Endocrino y Obesidad
-
-
-
-
-
Budapest, Ungarn, 1106
- Bajcsy-Zsilinszky Kórház
-
Budapest, Ungarn, 1134
- MH Egészségügyi Központ
-
Debrecen, Ungarn, 4031
- Debreceni Egyetem
-
Debrecen, Ungarn, H-4031
- Debreceni Egyetem
-
Debrecen, Ungarn, H-4032
- Debreceni Egyetem
-
Gyula, Ungarn, 5700
- Békés Megyei Központi Kórház
-
Kaposvár, Ungarn, 7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
Kaposvár, Ungarn, H-7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Debreceni Egyetem
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- Uni of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90057
- Velocity Clin Research LA
-
Santa Ana, California, Vereinigte Staaten, 92701
- Southern Cal Clinical Research
-
-
Connecticut
-
Waterbury, Connecticut, Vereinigte Staaten, 06708
- Chase Medical Research LLC
-
-
Florida
-
Fleming Island, Florida, Vereinigte Staaten, 32003
- Fleming Island Ctr for Clin Res
-
Hollywood, Florida, Vereinigte Staaten, 33024
- Encore Medical Research LLC
-
Miramar, Florida, Vereinigte Staaten, 33027
- South Broward Research LLC
-
Orlando, Florida, Vereinigte Staaten, 32825
- Florida Inst For Clin Res
-
Orlando, Florida, Vereinigte Staaten, 32825
- Florida Institute for Clinical research
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60607
- Cedar-Crosse Research Center
-
-
Kansas
-
Topeka, Kansas, Vereinigte Staaten, 66606
- Cotton O'Neil Clinical Research Center
-
-
Kentucky
-
Paducah, Kentucky, Vereinigte Staaten, 42001
- Advanced Internal Medicine, PLLC
-
-
Maryland
-
Hyattsville, Maryland, Vereinigte Staaten, 20782
- Medstar Research Institute_Hyattsville
-
Oxon Hill, Maryland, Vereinigte Staaten, 20745
- MD Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham & Women's Hospital
-
Methuen, Massachusetts, Vereinigte Staaten, 01844
- ActivMed Practice & Research LLC
-
-
Michigan
-
Troy, Michigan, Vereinigte Staaten, 48098
- Arcturus Healthcare, PLC
-
Troy, Michigan, Vereinigte Staaten, 48098
- Arcturus HC PLC Troy Med Res
-
-
Missouri
-
Chesterfield, Missouri, Vereinigte Staaten, 63005
- Clinical Research Professionals
-
City of Saint Peters, Missouri, Vereinigte Staaten, 63303
- StudyMetrix Research LLC
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12203
- AMC Community Endocrinology
-
-
North Carolina
-
Morehead City, North Carolina, Vereinigte Staaten, 28557
- Centricity Rsrch MHCity Multi
-
Statesville, North Carolina, Vereinigte Staaten, 28625
- Piedmont Healthcare/Research
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58104
- Lillestol Research LLC
-
Fargo, North Dakota, Vereinigte Staaten, 58104
- Plains Clinical Research Center, LLC_Fargo
-
-
Oklahoma
-
Norman, Oklahoma, Vereinigte Staaten, 73069
- Alliance for Multispec Res
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107-6810
- Jefferson Endocrinology Assocs
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15236
- Preferred Primary Care Physicians_Pittsburgh
-
-
South Dakota
-
Rapid City, South Dakota, Vereinigte Staaten, 57702
- Health Concepts
-
-
Tennessee
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Holston Medical Group
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Clinical Research Associates
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- MidState Endocrine Associates
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75230
- Velocity Clinical Res-Dallas
-
Houston, Texas, Vereinigte Staaten, 77024
- Victorium Clinical Research
-
Houston, Texas, Vereinigte Staaten, 77079
- PlanIt Research, PLLC
-
Houston, Texas, Vereinigte Staaten, 77061
- Synergy Groups Medical
-
Lampasas, Texas, Vereinigte Staaten, 76550
- Radiance Clinical Research
-
McKinney, Texas, Vereinigte Staaten, 75069
- Tekton Research
-
Waco, Texas, Vereinigte Staaten, 76708
- Hillcrest Family Health Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
- Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
- HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
- Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
- Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo subcutaneous
Placebo for subcutaneous treatment |
NNC0487-0111 placebo administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 1
NNC0487-0111 subcutaneous dose 1 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 2
NNC0487-0111 subcutaneous dose 2 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 3
NNC0487-0111 subcutaneous dose 3 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 4
NNC0487-0111 subcutaneous dose 4 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 5
NNC0487-0111 subcutaneous dose 5 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 6
NNC0487-0111 subcutaneous dose 6 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Placebo-Komparator: Placebo oral
Placebo for oral treatment |
NNC0487-0111 placebo administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 1
NNC0487-0111 oral dose 1 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 2
NNC0487-0111 oral dose 2 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 3
NNC0487-0111 oral dose 3 treatment |
NNC0487-0111 administered orally (in the mouth) |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in HbA1c
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
percent point |
From baseline (week 0) to end of treatment (week 36)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Relative change in body weight
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
percent |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
kg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
mmol/L |
From baseline (week 0) to end of treatment (week 36)
|
|
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
percent points |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body mass index (BMI)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
kg/m^2 |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in waist circumference
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
cm |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in average 24-hour systolic blood pressure (SBP)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Zeitfenster: From baseline (week 0) to end of study (week 40)
|
Count of events |
From baseline (week 0) to end of study (week 40)
|
|
Change in Urinary Albumin/Creatinine Ratio (UACR)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
Zeitfenster: At end of treatment (week 36)
|
Count of participant |
At end of treatment (week 36)
|
|
Change in eGFR creatinine- and cystatin C based CKD-EPI
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
mL/min/1.73 m^2 |
From baseline (week 0) to end of treatment (week 36)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.
- Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NN9490-7678
- U1111-1296-9708 (Andere Kennung: World Health Organization (WHO))
- 2023-509412-28 (Andere Kennung: European Medical Agency (EMA))
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .